Clinical decision-support only. For use by licensed dental professionals. Not a substitute for professional judgment or a complete drug reference. Always verify with primary sources.
← Back to search
Medication

Zolmitriptan

Anti-migraine (triptan, 5-HT1 agonist)

Brand names: Zomig

Oral health effects

  • Dysgeusia / oral paresthesia

    Bad taste and tingling/warmth in the mouth after dosing.

    Clinical management: Transient; reassure. Vasoconstrictor caution in uncontrolled cardiovascular disease.

  • Jaw, throat or neck tightness after dosing

    Tightness, pain or pressure in the jaw, throat, neck or chest commonly follows a dose (4–10% for neck/throat/jaw symptoms in trials); usually non-cardiac (label warning).

    Clinical management: If a patient reports jaw pain or tightness, ask whether they recently took a triptan before attributing it to a dental cause. Chest pain or symptoms that do not settle need medical assessment because rare cardiac events occur.

  • Dry mouth (xerostomia)

    Dry mouth was reported in 3–5% of patients in migraine trials (vs 2% on placebo).

    Clinical management: Usually short-lived after each dose; for frequent users, recommend water, sugar-free gum and fluoride if caries risk rises.

Sources

  1. A review and guide to drug-associated oral adverse effects-Dental, salivary and neurosensory reactions. Part 1. Teoh L, Moses G, McCullough MJ. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2019.
  2. Adverse drug events in the oral cavity. Yuan A, Woo SB. Oral surgery, oral medicine, oral pathology and oral radiology, 2015.
  3. Zolmitriptan prescribing information (FDA label) Asclemed USA, Inc. / DailyMed, 2025.